Reconciling the effects of PMS2 in different repeat expansion disease models supports a common expansion mechanism

This study demonstrates that PMS2 exhibits context-dependent, dose-responsive effects on repeat expansions across different disease models, supporting the hypothesis that diverse Repeat Expansion Diseases share a common underlying expansion mechanism.

The Gist

The Big Picture: A Family of Genetic Glitches

Imagine your DNA is a massive instruction manual for building and running a human body. Sometimes, a specific sentence in that manual gets copied over and over again by mistake. Instead of the word "cat" appearing once, you end up with "catcatcatcatcat."

This is called a Repeat Expansion. It happens in over 45 different diseases (like Huntington's disease or Fragile X syndrome). Usually, the more copies there are, the worse the disease gets. Right now, there is no cure for these diseases, so scientists are desperate to figure out how these extra copies get added so they can stop the process.

The Confusing Detective: PMS2

Scientists have identified a "repair crew" in our cells called the Mismatch Repair (MMR) system. Its job is to find typos in the DNA and fix them. One specific member of this crew is a protein called PMS2.

For a long time, scientists were confused about PMS2 because it seemed to have a split personality:

• In some disease models (like Huntington's), removing PMS2 made the repeats get longer (worse). This suggested PMS2 was a hero trying to stop the expansion.
• In other models (like Fragile X), removing PMS2 made the repeats get shorter or disappear. This suggested PMS2 was a villain helping the repeats grow.

This contradiction made researchers wonder: Do these different diseases work in completely different ways? If they do, we might need a different cure for every single disease.

The Experiment: Testing Two Models at Once

The researchers in this paper decided to test this idea using two different "mouse models" of disease: one for Fragile X (FXD) and one for Huntington's (HD). They wanted to see what happened to the repeat lengths when they changed the amount of PMS2 in the mice.

Think of PMS2 like a volume knob on a stereo, and the DNA repeats like a song that keeps getting louder (longer).

1. Turning the volume down a little (Heterozygous mice): When they reduced PMS2 by half, the repeats got slightly longer in the brain and spinal cord.
2. Turning the volume all the way off (Null mice): When they removed PMS2 completely, the results were a mix:
   • In the brain, the repeats got even longer. (So, PMS2 was acting as a brake here).
   • In the colon and testes, the repeats stopped growing entirely. (So, PMS2 was acting as an engine here).

The "Aha!" Moment: The researchers realized that PMS2 isn't just a hero or a villain. It's a chameleon. Depending on the tissue (the room the stereo is in) and how much of it is present, it can either speed up the expansion or slow it down.

The Secret Weapon: The "Scissors"

To understand why this happens, the scientists looked at the tools PMS2 carries. PMS2 has a specific part called a nuclease domain. You can think of this as a pair of molecular scissors that cuts DNA.

They created a version of PMS2 where they "broke" the scissors (a mutation called D696N).

• When they added the normal PMS2 (with working scissors) to cells, the repeats started growing again.
• When they added the broken PMS2 (scissors that can't cut), the repeats stayed short.

Conclusion: The "scissors" are essential. PMS2 needs to be able to cut the DNA to help the repeats expand.

The Unified Theory: One Mechanism, Different Outcomes

The paper proposes a single, unified theory to explain the confusion:

Imagine the DNA repeat is a tangled knot with two loops sticking out.

• The "Engine" Scenario: In some tissues, the repair crew (specifically another protein called MLH3) cuts the DNA in a way that creates a mess. PMS2 comes in, uses its scissors, and accidentally helps tie the knot tighter, adding more loops. This causes expansion.
• The "Brake" Scenario: In other tissues, the knot is already messy. If PMS2 cuts it, it fixes the knot perfectly, removing the extra loops. If you remove PMS2 in this scenario, the knot stays messy and keeps growing because the "fixer" is gone.

Why This Matters

This is a huge deal for patients.

1. One Cure for All: Since the same mechanism (the PMS2 scissors) is driving the problem in both Huntington's and Fragile X, we don't need 45 different cures. We might be able to develop one drug that targets PMS2 to stop the expansion in all these diseases.
2. Precision Medicine: Because PMS2 acts differently in different organs, doctors will need to be careful. A drug that stops expansion in the brain might accidentally stop it in the testes (which could affect fertility) or vice versa. We need to tune the "volume knob" just right for the specific tissue we want to treat.

In short: The paper solves a mystery by showing that the "bad guy" and the "good guy" are actually the same person wearing different masks. By understanding how that person switches masks, we can finally figure out how to stop the disease.

Technical Summary

1. Problem Statement

Repeat Expansion Diseases (REDs) are a group of over 45 neurodegenerative and neurodevelopmental disorders caused by the pathological expansion of short tandem repeats (STRs). While the Mismatch Repair (MMR) pathway is known to modulate these expansions, the specific role of the protein PMS2 (a component of the MutL$\alpha$ complex) has been contradictory across different disease models:

• Protective Role: In mouse models of Huntington's Disease (HD, CAG repeats) and Friedreich's Ataxia (FRDA, GAA repeats), loss of PMS2 increased expansion, suggesting PMS2 normally suppresses instability.
• Promotive Role: In models of Myotonic Dystrophy Type 1 (DM1, CTG repeats) and Fragile X-related Disorders (FXD, CGG repeats), loss of PMS2 decreased expansion, suggesting PMS2 is required to drive the mutation.

This conflict raised the possibility that REDs utilize fundamentally different molecular mechanisms for expansion, complicating the development of universal therapies. The authors aimed to resolve this paradox to determine if a common expansion mechanism exists.

2. Methodology

The study employed a multi-pronged approach using mouse models and mouse embryonic stem cells (mESCs):

• Mouse Models:

  • FXD Model: Mice with expanded CGG repeats in the Fmr1 gene.
  • HD Model: zQ175 mice with expanded CAG repeats in the Htt gene.
  • Genetic Crosses: Both RED models were crossed with Pms2 null mice to generate Wild Type (WT), Heterozygous (Pms2+/-), and Nullizygous (Pms2-/ -) offspring.
  • Tissue Analysis: Repeat instability was measured via capillary electrophoresis in various tissues (striatum, cortex, colon, testes, liver) from 4- and 8-month-old males.

• Cellular Models (mESCs):

  • Double Knock-In (dKI) mESCs: Cells containing both FXD (180 repeats) and HD (215 repeats) alleles were generated.
  • CRISPR-Cas9: Used to knock out Pms2 in dKI-mESCs.
  • Inducible Expression: A doxycycline (DOX)-inducible system was used to reintroduce either Wild Type (WT) PMS2 or a nuclease-dead mutant (D696N) into Pms2-/ - dKI-mESCs. This allowed for precise titration of PMS2 protein levels.

• Molecular Analysis:

  • Western Blotting: Quantified PMS2, MLH1, and $\beta$-actin levels to correlate protein abundance with expansion rates.
  • Repeat Instability Assays: Calculated the Expansion Index (EI) and measured repeat number changes relative to the inherited allele.

3. Key Contributions

• Resolution of the PMS2 Paradox: The study demonstrates that the contradictory effects of PMS2 are not due to different disease mechanisms, but rather a dose-dependent and tissue-specific dual role of PMS2.
• Nuclease Dependency: The authors prove that PMS2's ability to promote expansion is strictly dependent on its endonuclease activity (specifically the D696 residue).
• Unified Mechanism Hypothesis: The data supports a model where PMS2 can either protect against or drive expansion depending on its concentration relative to other MMR factors (like MLH3 and PMS1) and the specific cellular context.

4. Key Results

A. Dual Role in Mouse Tissues (FXD and HD Models)

In both FXD and HD mouse models, the effect of PMS2 loss was tissue-dependent and dose-dependent:

• Neural Tissues (Striatum, Cortex):
  • Pms2 heterozygosity (+/-) caused a slight increase in expansion.
  • Pms2 nullizygosity (-/-) caused a further significant increase in expansion.
  • Interpretation: In these tissues, PMS2 acts as a protective factor (suppressing expansion). Its absence leads to hyper-expansion.
• Non-Neural Tissues (Colon, Testes):
  • Pms2 nullizygosity (-/-) resulted in a loss or significant reduction of expansions compared to WT or heterozygous mice.
  • Interpretation: In these tissues, PMS2 is required to drive expansion. Its absence prevents the mutation.
• Heterozygous Anomaly: In some tissues (e.g., testes), heterozygous mice showed higher expansion than WT. The authors hypothesize this is due to reduced PMS2 levels allowing PMS1 (a competing MutL partner) to bind MLH1 more effectively, potentially driving expansion via the MutL$\beta$ complex.

B. PMS2 Requirement in mESCs

• Complete Loss: In Pms2-/ - dKI-mESCs, no expansion occurred for either FXD or HD repeats; instead, slight contractions were observed. This confirms PMS2 is essential for expansion in this cellular context.
• Dose-Response: Re-introducing WT PMS2 via DOX induction restored expansion.
  • Low-to-moderate PMS2 levels led to a progressive increase in expansion rates.
  • Peak expansion occurred at 30 ng/mL DOX (comparable to WT levels).
  • High PMS2 levels (supra-physiological) led to a decrease in expansion, suggesting that excess PMS2 shifts the balance toward error-free repair or competes with expansion-promoting complexes.

C. The Critical Role of the Nuclease Domain

• When the Pms2-/ - mESCs were induced to express the D696N mutant (nuclease-dead), no expansion occurred at any DOX concentration, even when protein levels matched WT.
• This confirms that the endonuclease activity of PMS2 is the specific mechanism driving repeat expansion, distinguishing it from its role in standard DNA repair.

5. Significance and Implications

• Common Mechanism: The findings strongly support the hypothesis that different REDs share a common expansion mechanism. The apparent contradictions in previous literature were due to the complex, non-linear relationship between PMS2 concentration and expansion outcomes in different tissues.
• Therapeutic Strategy: Since PMS2 promotes expansion in specific contexts (via its nuclease domain) and protects in others, therapeutic strategies targeting the MMR pathway must be carefully calibrated.
  • Simply inhibiting PMS2 might be beneficial in tissues where it protects (like the brain in HD) but detrimental in tissues where it drives expansion (like the testes in FXD).
  • Targeting the nuclease domain specifically could offer a way to block expansion without completely abolishing MMR function, potentially reducing toxicity.
• Mechanistic Insight: The study proposes a model where expansion results from the processing of two loop-outs in the DNA substrate. PMS2 (MutL$\alpha$) and MLH3 (MutL$\gamma$) act as endonucleases. The specific combination of cleavage events determines whether the loops are incorporated (expansion) or repaired correctly. PMS2 levels dictate which complex dominates and how the DNA is processed.

In conclusion, this paper reconciles conflicting data by showing that PMS2 acts as a "switch" that can either promote or suppress repeat expansion depending on tissue-specific factors and protein dosage, unifying the understanding of RED pathogenesis.